secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001140361-24-037322
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%
-----------------------------------------------------------------------------

- Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.
- Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.
- Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).
- XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.
- Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/0001140361-24-037322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124037322/ef20034059_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-037322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer